2009
DOI: 10.1128/aac.00366-09
|View full text |Cite
|
Sign up to set email alerts
|

Activity of SQ641, a Capuramycin Analog, in a Murine Model of Tuberculosis

Abstract: New delivery vehicles and routes of delivery were developed for the capuramycin analogue SQ641. While this compound has remarkable in vitro potency against Mycobacterium tuberculosis, it has low solubility in water and poor intracellular activity. We demonstrate here that SQ641 dissolved in the water-soluble vitamin E analogue ␣-tocopheryl polyethylene glycol 1000 succinate (TPGS) or incorporated into TPGS-micelles has significant activity in a mouse model of tuberculosis.SQ641 is an analogue of capuramycin (C… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
38
0

Year Published

2009
2009
2016
2016

Publication Types

Select...
5
3
1

Relationship

1
8

Authors

Journals

citations
Cited by 58 publications
(38 citation statements)
references
References 8 publications
0
38
0
Order By: Relevance
“…Capuramycins effectively and rapidly kill several species of mycobacteria in vitro (25,26), and they have recently been demonstrated to be very effective and nontoxic anti-TB drugs using a mouse model (25,27), suggesting that these compounds have clinical promise. Given the exciting potential of this family of antibiotics, it is of significant interest to elucidate the potential mechanism(s) of resistance to capuramycins prior to utilization in the clinic, thus serving as the foundation for limiting the onset of capuramycin-resistant strains that is an inevitable consequence of the selection process.…”
Section: Discussionmentioning
confidence: 99%
“…Capuramycins effectively and rapidly kill several species of mycobacteria in vitro (25,26), and they have recently been demonstrated to be very effective and nontoxic anti-TB drugs using a mouse model (25,27), suggesting that these compounds have clinical promise. Given the exciting potential of this family of antibiotics, it is of significant interest to elucidate the potential mechanism(s) of resistance to capuramycins prior to utilization in the clinic, thus serving as the foundation for limiting the onset of capuramycin-resistant strains that is an inevitable consequence of the selection process.…”
Section: Discussionmentioning
confidence: 99%
“…Studies into the biological activity of A-500359 A, the major congener isolated from S. griseus SANK 60196, and several semisynthetic analogues have revealed a potential utility of these natural products as anti-tuberculosis antibiotics (9,10). For example, SQ641 and SQ922, two leads under preclinical development by Sequella (Rockville, MD), have been shown to have several clinically desirable attributes, including in vitro activity against multiple-drug-resistant strains of Mycobacterium tuberculosis (the primary causative agent of tuberculosis); high efficacy in a murine model of tuberculosis; rapid kill time in vitro and in vivo; and no toxicity to mice (11)(12)(13)(14)(15)(16)(17). Given the widespread documentation of extensively drug-resistant M. tuberculosis and the recent reality of totally drug-resistant M. tuberculosis (18), the development of drugs with novel targets, such as the capuramycin-type antibiotics, makes them attractive leads for tuberculosis chemotherapy (19,20).…”
Section: Capuramycin-type Antibiotics Include A-500359s Frommentioning
confidence: 99%
“…Other new molecular entities, such as the more recently described benzothiazinones (11) and capuramycin derivatives (13), are supported by in vitro and in vivo data but as yet have not been evaluated in human trials. Nonetheless, more than a decade has elapsed since the first description of PA-824.…”
mentioning
confidence: 83%